SCHEMBL2932286

SCHEMBL2932286

Fc1ccc2c(c1)[nH]c1c3ccc(C(F)(F)F)cc3oc21

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KCNMA1 Q12791 1/20 0.47
KIF11 P52732 11/20 0.41
PIM1 P11309 1/20 0.38
PIM3 Q86V86 1/20 0.38
MAPT P10636 1/20 0.38
CDK4 P11802 1/20 0.37
CCND1 P24385 1/20 0.37
CCNB2 O95067 1/20 0.37
CDK1 P06493 1/20 0.37
CCNB1 P14635 1/20 0.37
CCNA2 P20248 1/20 0.37
CDK2 P24941 1/20 0.37
CCNA1 P78396 1/20 0.37
CDK5 Q00535 1/20 0.37
CDK5R1 Q15078 1/20 0.37
CCNB3 Q8WWL7 1/20 0.37
CA12 O43570 1/20 0.36
CA9 Q16790 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2931271 0.84 KCNMA1 (0.50) KCNMA1KIF11CDK4CCND1CCNB2
SCHEMBL2934874 0.80 KCNMA1 (0.50) KCNMA1KIF11PIM1PIM3CDK4
SCHEMBL15128425 0.80 PPARG (0.48) MAPTCDK4CCND1CCNB2CDK1
SCHEMBL2932491 0.75 KCNMA1 (0.50) KCNMA1KIF11PIM1PIM3CDK4
SCHEMBL2925140 0.74 KCNMA1 (0.61) KCNMA1KIF11PIM1PIM3MAPT
SCHEMBL2930924 0.74 KCNMA1 (0.49) KCNMA1KIF11PIM1PIM3CDK4
SCHEMBL2931881 0.74 KCNMA1 (0.57) KCNMA1KIF11PIM1PIM3CDK4
SCHEMBL2932784 0.73 KCNMA1 (0.57) KCNMA1KIF11PIM1PIM3CDK4
SCHEMBL2930598 0.73 KCNMA1 (0.46) KCNMA1KIF11MAPTCCNB2CDK1
SCHEMBL13564564 0.71 PIM1 (0.45) KCNMA1KIF11PIM1PIM3MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7812177-B2 Potassium channel opener having benzofuroindole skeleton ANYGEN CO., LTD. (KR) 2010-10-12 US disclosed
EP-1861092-B1 POTASSIUM CHANNEL OPENER HAVING BENZOFUROINDOLE SKELETON ANYGEN CO LTD (KR) 2010-09-15 EP disclosed
EP-1861092-A4 POTASSIUM CHANNEL OPENER HAVING BENZOFUROINDOLE SKELETON ANYGEN CO LTD (KR) 2009-04-15 EP disclosed
US-20080194837-A1 Potassium Channel Opener Having Benzofuroindole Skeleton ANYGEN CO., LTD. (KR) 2008-08-14 US disclosed
EP-1861092-A1 POTASSIUM CHANNEL OPENER HAVING BENZOFUROINDOLE SKELETON Anygen Co., Ltd. (KR) 2007-12-05 EP disclosed
WO-2006096030-A1 POTASSIUM CHANNEL OPENER HAVING BENZOFUROINDOLE SKELETON ANYGEN CO., LTD. (KR) 2006-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194837-A1 Potassium Channel Opener Having Benzofuroindole Skeleton KCNJ2, KCNN3, KCNH2 KCNMA1 41/4885KIF11 636/4885PIM1 3440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.